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Methods: Understanding of the informed consent document was assessed in 613 community-
dwelling patients with mild-to-moderate AD enrolled in a randomized, placebo-controlled trial.
Associations were examined between clinically determined capacity to consent and (1) patient demo-
graphics and clinical characteristics and (2) the Informed Consent Questionnaire (ICQ), an objective
measurement of a participant’s factual understanding and perceived understanding.
Results: A total of 453 (74%) participants were determined to have capacity to consent by clinical
judgment. ICQ perceived understanding, race, measures of cognitive function, and caregiver time
were all significantly associated with the determination of capacity in multivariate analyses.
Discussion: We found a significant association between capacity and disease severity level, caregiver
time, race, and ICQ perceived understanding.
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Obtaining informed consent is considered by researchers
and the general public as a critical element for ethical human
research [1–4]. Nevertheless, current informed consent
practices are often inadequate, particularly among vulnerable
individuals, such as persons with Alzheimer’s disease (AD)
[5,6]. In addition, the strength of the relationship between. This is an open access article under the CC BY-NC-ND license (http://
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remains ill-defined [6–9].
One of the ethical principles of informed consent is
respect for persons, which includes two requirements: first,
individuals should be treated as autonomous agents, and sec-
ond, those with diminished autonomy are entitled to extra
protection [10]. Because the ability of AD patients to
make informed decisions is often questionable, it is essential
to determinewhether patients have adequate capacity to con-
sent [11–13]. Despite this, there is no consensus on how to
reliably assess decision-making capacity in AD research
subjects [14–16]. In addition, there are no consistent or
clear policies for researchers or institutional review boards
(IRBs) regarding the involvement of adults with dementia
or their surrogates in clinical research trials [14,17].
We developed a capacity assessment instrument that
focused on understanding of factual information about an AD
clinical trial and the patient’s perceived understanding (partic-
ipant’s subjective beliefs about understanding). The instrument
was designed to provide an objective measure to assist re-
searchers and oversight committees in balancing the need to
(1) protect the right of individuals to decide for themselves
whether to participate and (2) protect the collective rights of
vulnerable individuals for ethical and regulatory imperatives.
The assessment was not designed to address other important
components of capacity such as appreciation of the significance
of the decision, reasoning, or expression of choice. These ele-
ments were components of the investigator’s judgment of ca-
pacity that were separate from our capacity assessment.2. Methods
2.1. Objectives
The objectives of this study were to (1) assess the associ-
ations between capacity to consent as determined by site
investigators and an objective measure of a participant’s
understanding of the study, demographics, and cognitive
and functioning assessments at the time of consent; and
(2) examine the relationship between capacity to consent
as determined by the site investigator and a participant’s
perceived understanding of the study.
2.2. Study design
This informed consent study was incorporated in the
Department of Veterans Affairs (VA) Cooperative Studies
Program placebo-controlled, randomized clinical trial to
assess the effectiveness of alpha-tocopherol, memantine,
and the combination vs. placebo on clinical progression in
patients with AD (CSP#546). Details regarding the
CSP#546 design and study results have been published
[18,19]. Briefly, mild-to-moderate AD patients were ran-
domized to receive one of the four treatments. The mean
(SD) follow-up time was 2.3 (1.2) years with treatment dura-
tion ranging from 6 to 48months. The studywas approved by
the IRB at each of the 14 participating VA medical centers.2.3. Patients
Veterans with possible or probable AD of mild-to-
moderate severity (Mini-Mental State Examination [MMSE]
total score between 12 and 26 inclusive) were recruited
from 14 VAmedical centers between August 2007 andMarch
2012 [18,19]. All participants or their surrogates provided
written informed consent.
2.4. Informed consent
Before initiating the study, study coordinators and clinical
investigators were trained to assess capacity using a 17-item
Informed Consent Questionnaire (ICQ) aimed at clarifying
a participant’s understanding of the study and his/her rights
as a research subject (Fig. 1). This study-specific tool was
developed to provide a simple, consistent, and objective mea-
sure of both understanding and perceived understanding to
assist investigators in their assessment of capacity.
During the informed consent process, study coordinators
and/or site investigators described the CSP#546 study, its
purpose and procedures, and the risks and benefits of partic-
ipation. Patients and caregivers were given an opportunity to
read and take home the informed consent document and ask
questions. Before completing the consent process, patients
were asked to complete the ICQ without assistance from
their caregivers. Questionnaire responses were reviewed
with the patient, and all items answered incorrectly were
clarified. After the discussion, the ICQ was readministered.
If the participant was able to adequately understand the study
on the first or second administration and/or the investigator
believed that the participant had adequate decisional capac-
ity and was making a voluntary decision, the participant was
judged to have capacity to consent. If it was determined that
the participant lacked capacity, the investigator requested
assent from the patient and proxy consent from a surrogate.
While the ICQ was used by investigators as a tool to help
determine capacity, the final decision was ultimately based
on the primary site investigator’s clinical judgment. The
decision about capacity was also carried out according to
(1) local VA policy, which typically requires consultation
with an independent clinician if it is determined that an indi-
vidual may not have capacity, and (2) state laws, which vary
and typically only address court-appointed legally autho-
rized representatives and surrogate decision makers.
If a participant with adequate decisional capacity at enroll-
ment appeared to have lost capacity during follow-up, or his/
her cognitive function declined to a severe level (defined as
MMSE,15), the site investigator repeated the informed con-
sent process and sought surrogate consent if needed.
2.5. Outcome measures
The primary outcome measures were (1) the clinical
investigator’s determination of a patient’s capacity to con-
sent and (2) the ICQ measurement of a patients’ knowledge
and understanding of the information in the consent form as
Fig. 1. Informed Consent Questionnaire.
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first 14 questions of the ICQ tested understanding of the
important elements of the study including potential benefits
and risks. To be judged to have capacity as measured by the
ICQ, the participant had to answer 70% of questions 1 to 10
and 100% of questions 11 to 14 correctly on the first or
second administration. With input from the human rights
committee at the coordinating center, the questions and the
scoring algorithm were developed by the study’s planning
committee based solely on face validity. The ICQ and its
scoring were also reviewed and approved by the IRBs at
each participating site.The ICQ included the assessment of participants’
perceived understanding, that is, participants’ beliefs about
their understanding, and whether they felt the benefits and
risks were adequately explained. Perceived understanding
was assessed with ICQ items 15 to 17 derived from the vali-
dated ICQ-4 [20]. The score for each of these questions
ranged from 0 to 3 (total score range: 0–9).
The primary outcome measure of the CSP#546 study was
the ADCooperative Study/Activities of Daily Living (ADCS/
ADL) inventory to assess functional abilities [21]. Secondary
clinical outcome measures included the MMSE [22] and the
AD Assessment Scale—Cognitive Subscale (ADAS-cog)
Table 1
Baseline characteristics of the study participants according to site
investigator’s determination of capacity at enrollment
No capacity Capacity
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atric Inventory [24] to assess psychological and behavioral
problems; and the Caregiver Activity Survey (CAS) [25] to
measure caregivers’ time required to care for the patient.Characteristic (N 5 160) (N 5 453) P value
Age (y) .35
Mean 6 SD 79.2 6 7.0 78.6 6 7.1
Sex, n (%) .98
Male 155 (97) 439 (97)
Female 5 (3) 14 (3)
Race, n (%)* .02
White 129 (81) 400 (88)
Black 1 other 31 (19) 53 (12)
Ethnic group, n (%) .60
Hispanic 19 (12) 47 (10)
Education, n (%) .04
Less than high school
graduation
46 (29) 91 (20)
High school graduation 58 (36) 149 (33)
Some college 29 (18) 106 (23)
College graduation or 27 (17) 107 (24)2.6. Statistical analysis
A k coefficient was calculated to assess the agreement
between the ICQ and the clinical investigators’ assessment
of capacity [26]. Sensitivity analyses examining different
criteria for determining a “passing” ICQ score on the level
of agreement were also conducted. The associations between
capacity, demographics, ICQ perceived understanding
scores, and the AD cognitive and functioning measures
were analyzed by univariate and multivariate logistic regres-
sion. All tests of significance were conducted at the 5% level
without correction for multiplicity. Analyses were performed
using SAS, version 9.1 (SAS Institute, Inc., Cary, NC).advanced degree
Alzheimer’s disease assessments,
mean 6 SD
ADCS-ADLy 49.1 6 14.5 59.5 6 13.1 ,.001
CASz 11.1 6 16.0 5.3 6 7.9 ,.001
NPIx 13.6 6 14.6 12.1 6 13.0 .24
ADAS-Cogk 24.9 6 9.4 16.6 6 6.8 ,.001
MMSE{ 18.4 6 3.8 22.0 6 3.0 ,.001
Alzheimer’s disease severity ,.001
Mild Alzheimer’s disease, n
(%), MMSE score 20–26,
62 (15) 348 (85)
Moderate Alzheimer’s disease,
n (%), MMSE score 12–19
98 (48) 105 (52)
NOTE. Values in bold indicate statistical significance at the .05 level.
Abbreviations: SD, standard deviation; ADCS-ADL, Alzheimer’s Dis-
ease Cooperative Study/ Activities of Daily Living; CAS, Caregiver Activ-
ity Survey; NPI, Neuropsychiatric Inventory; ADAS-Cog, Alzheimer’s
Disease Assessment Scale–Cognitive portion; MMSE, Mini-Mental State
Examination.
*Race and ethnicity were self-identified by participants; other race
included American Indian or Alaska Native (2), Asian (1), and Native
Hawaiian or Other Pacific Islander (1).
yRange, 0 to 78; higher scores 5 better functioning.
zMeasures caregiver time in caring for patients with dementia, summing
total hours spent in a day on 6 caregiving tasks; range, 0 to 144 hours; higher
scores 5 more time spent on caregiving.
xAssesses frequency and severity of psychological and behavioral prob-
lems in patients with dementia; range, 0 to 144; higher scores 5 more
frequent and/or severe behavioral problems.
kAssesses cognitive function in the areas of memory, language, and praxis
functions; range, 0 to 70; higher scores 5 worse functioning.
{Range, 0 to 30; higher scores 5 better functioning.3. Results
Between August 7, 2007, and March 31, 2012, 613 veter-
ans with mild-to-moderate AD were randomized. A total of
453 (74%) had capacity and 160 (26%) lacked capacity to
consent at enrollment as determined by the site investigator.
Eighty-three (18%) participants who had capacity at enroll-
ment were reassessed and determined to have lost capacity
during study follow-up. Significant associations with capac-
ity were found for race, education, the ADCS/ADL Inven-
tory, the MMSE, the ADAS-cog, and the CAS (Table 1).
Determination of capacity by site investigators and the
ICQ was in agreement on 502 (82%) participants (Table 2;
k 0.60; 95% CI, 0.54–0.66). We examined whether there
were any differences in population where investigators and
the ICQ were in agreement compared to when they
disagreed. We found that the mean perceived understanding
score was significantly lower (6.7 vs. 7.4; P5 .006) and time
spent by caregivers was borderline higher (7.0 vs. 4.8 hours:
P5 .05) for patients the investigators determined had capac-
ity when the ICQ did not (n5 99) compared to those where
both the investigator and the ICQ agreed on capacity
(n 5 354). For those patients whom the investigators had
determined lacked capacity when the ICQ rated them as hav-
ing capacity (n 5 12), the mean perceived understanding
score was significantly higher (6.6 vs. 4.8; P 5 .004)
compared to those when both the investigator and the ICQ
agreed on lack of capacity (n 5 148).
The sensitivity analyses examining different cut points
for a “passing grade” revealed that the highest level of agree-
ment (k 0.71; 95% CI, 0.64–0.78) was achieved by keeping
the requirement of 70% correct for questions 1 to 10 but
reducing the requirement to at least 3 out of 4 answers to
be correct on questions 11 to 14.
There were significantly more correct responses for those
with investigator-determined capacity versus those without
capacity on all ICQ questions (P , .001) except for #10:“Will you be paid for participating in this study?”
(Table 3). Correct responses on question 1 through 14 ranged
from 68% to 99% for participants with capacity and from
11% to 69% for those without capacity. Questions that
were answered incorrectly most frequently were #2 (identi-
fication of the medications used in the study [11%]) and #12
(identification of a possible side effect of treatment [18%]).
Perceived understanding scores were also significantly
different by investigator-determined capacity. The mean
Table 2
Association between capacity as measured by the Informed Consent
Questionnaire and capacity as determined by the site investigator
Informed Consent
Questionnaire determination
of capacity, n (%)
Site investigator–
determined capacity,
n (%)
TotalNo capacity Capacity
No capacity 148 (93) 99 (22) 247 (40)
Capacity 12 (7) 354 (78) 366 (60)
Total 160 (26) 453 (74) 613
NOTE. Number of observed agreements: 502 (81.9% of the observa-
tions); Number of agreements expected by chance: 335 (54.6% of the obser-
vations): k (standard error) 5 0.60 (0.03); 95% CI, 0.54 to 0.66.
Table 3
Informed Consent Questionnaire: Participant correct responses by site
investigator–determined capacity at enrollment
Correct response, n (%)*
No capacity
(N 5 160)
Capacity
(N 5 453)
1. How long will you be in the study? 81 (51) 427 (94)
2. Please mark the boxes for the pills that you
might receive in this study.
17 (11) 308 (68)
3. During the study, will you know exactly
which medications you will receive?
83 (52) 398 (88)
4. Will you be able to choose which
medications you will get in this study?
86 (54) 434 (96)
5. Will blood be drawn for this study? 104 (65) 442 (98)
6. During the study, will you be given tests to
see if your memory has changed?
103 (64) 445 (99)
7. If you choose not to be in this study, will
this change your regular treatment?
94 (59) 442 (98)
8. Once you begin this study, are you free to
stop at any time?
110 (69) 436 (97)
9. If you drop out of this study, will this
change your regular care?
97 (61) 436 (97)
10. Will you be paid for participating in
this study?y
91 (57) 339 (75)
Number of correct responses for questions
1–10, mean (SD)
5.6 (2.9) 9.1 (1.2)
11. Can the study medications have
side effects?
93 (58) 441 (98)
12. Name 1 possible side effect of the study
medications:
29 (18) 375 (85)
13. Is the study guaranteed to help you? 86 (54) 423 (94)
14. Is the study voluntary? 111 (69) 447 (99)
Number of correct responses for questions
11–14, mean (SD)
2.0 (1.3) 3.7 (0.6)
Perceived understanding, mean (SD)z
15. Do you feel that you understand the
study?
2.0 (0.8) 2.3 (0.7)
16. Do you feel the potential benefits of the
study were adequately explained?
2.1 (0.8) 2.5 (0.7)
17. Do you feel the potential risks of the
study were adequately explained?
2.1 (0.8) 2.5 (0.7)
Total perceived understanding score 4.9 (3.2) 7.2 (1.9)
Abbreviation: SD, standard deviation.
*Missing responses on questions ranged for 20 to 39 participants without
capacity and 0 to 6 for those with capacity.
yP 5 .42 for question 10; all other P values , .0001.
zPerceived understanding (ICQ items 15, 16, and 17) responses are scored
as follows: not at all5 0; somewhat5 1; mostly5 2; yes, completely5 3.
Total perceived understanding score 5 total of items 15, 16, and 17;
range 5 0 to 9.
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with capacity was 7.2 (1.9) and 4.9 (3.2) for those without
capacity (P , .001). On average, participants with capacity
believed that they understood the trial and that the risks and
benefits were adequately explained (Table 3). The Pearson
correlation coefficient for perceived understanding and num-
ber of correct responses for questions 1 to 10 was 0.24 for
those with capacity, 0.67 for those without capacity, and
0.60 overall. For questions 11 to 14, it was 0.29 for those
with capacity, 0.58 for those without capacity, and 0.58 over-
all (all P values,.001).
Perceived understanding score, race, MMSE, ADAS-
cog, and CAS were all significantly associated with
investigator-determined capacity after adjustment in multi-
variate analysis (Table 4). The mean (SD) MMSE score for
those with capacity was 22.0 (3.0) and 18.4 (3.8) for those
without capacity. The odds of a participant lacking capacity
to consent increased by 26% for every 1-point decrease on
the MMSE in a univariate analysis and by 13% after adjust-
ment in the multivariate analysis (P , .001). When the
MMSE total score was divided into ranges that define
mild (20–26) versus moderate (12–19) AD, the odds for
lacking capacity decreased by 81% for the milder group.
Of the 203 participants with moderate AD, 48% (n598)
lacked capacity; of the 410 with mild AD, only 15%
(n562) lacked capacity.
The mean (SD) ADAS-cog score for those with capacity
was 16.6 (6.8) and 24.9 (9.4) for those without capacity. For
every 1-point increase on the ADAS-cog, the odds of lacking
capacity increased by 7% in the adjusted multivariate anal-
ysis (P 5 .001). The mean (SD) hours on the CAS for those
with capacity was 5.3 (7.9), and for those without capacity, it
was 11.1 (16.0). In the adjusted analysis, the odds of lacking
capacity increased by 3% for every hour increase in care-
giver time (P 5 .01). White race was also associated with
a greater likelihood of being determined to have capacity.4. Discussion
We assessed the relationships between clinically deter-
mined capacity to consent and (1) patient demographics,
(2) an objective measurement of understanding andperceived knowledge about the study, and (3) standard AD
assessment measures. We found that the strength of the
agreement between the ICQ score and the clinical investiga-
tor’s determination of capacity was “good” (k 0.60) [26]. A
stronger agreement was expected because all investigators
reviewed the ICQ as part of their determination of capacity.
When examining differences between investigators’ and the
ICQs’ determinations of capacity, we found significant
differences in perceived understanding scores, which may
indicate that investigators gave less weight to participants’
perceptions about their understanding when determining
Table 4
Association between capacity as determined by the site investigator and
demographic, ICQ perceived understanding scores, and Alzheimer’s disease
cognitive and functioning measures
Baseline measure
Univariate analyses:
odds ratio estimates
for no capacity
Multivariate analysis:*
odds ratio estimates
for no capacity
Odds ratio
(95% CI) P value
Odds ratio
(95% CI) P value
Education level 0.78 (0.66–0.93) .005 0.97 (0.78–1.20) .75
Race (white vs.
black 1 other)
1.84 (1.12–2.95) .02 2.22 (1.23–4.01) .008
Perceived
understanding
total score
0.69 (0.64–0.75) ,.001 0.77 (0.70–0.84) ,.001
Alzheimer’s
disease
severity:
MMSE mild
(20–26) vs.
MMSE
moderate
(12–19)
0.19 (0.13–0.28) ,.001 — —
MMSE 0.74 (0.70–0.79) ,.001 0.87 (0.80–0.94) ,.001
ADAS-Cog 1.14 (1.11–1.17) ,.001 1.07 (1.03–1.10) ,.001
ADCS-ADL 0.95 (0.94–0.96) ,.001 0.99 (0.97–1.01) .39
CAS 1.05 (1.03–1.07) ,.001 1.03 (1.01–1.05) .02
NPI 1.01 (0.99–1.02) .24 0.98 (0.97–1.00) .06
Abbreviations: ICQ, Informed Consent Questionnaire; CI, confidence
interval; MMSE,Mini-Mental State Examination; ADAS-Cog, Alzheimer’s
Disease Assessment Scale–Cognitive portion; ADCS-ADL, Alzheimer’s
Disease Cooperative Study/ Activities of Daily Living; CAS, Caregiver
Activity Survey; NPI, Neuropsychiatric Inventory.
*Full multivariate analyses excluded severity level because it was derived
from the MMSE score and was highly correlated with it (correlation
coefficient 5 0.84).
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many investigators reported that it was very helpful, partic-
ularly in patients with milder impairments. Several of the
IRBs involved in the study expressed their support for using
the ICQ noting the need for more objective measures to
assess capacity.
Significant associations were found between the investiga-
tors’ determination of capacity and perceived understanding,
educational level, race, and AD assessments. The association
between race and capacity remained significant after control-
ling for severity level, education, and ICQ scores. It is unclear
whether there was any racial bias in the assessment of capac-
ity or whether race was a proxy for another important unmea-
sured variable related to capacity or the need for surrogate
consent, such as socioeconomic status, social support, or so-
cial networks [27]. It is also possible that racial differences
in capacity were related to racial differences in literacy, qual-
ity of education, comorbidities, or specific aspects of AD pro-
gression that are not fully controlled for by the study’s
cognitive or functional assessments [28–30].
Cognitive impairment measured by the MMSE and the
ADAS-cog were both significantly related to capacity in uni-
variate and multivariate analysis. This finding is similar to astudy that found that the level of cognitive functioning
measured by the MMSE was the best predictor of decisional
capacity [31]. There is also some evidence that clinicians’
assessment of capacity in AD is partially related to particular
aspects of a patients’ cognitive function such as conceptual-
ization and memory functioning [32]. In our study, although
the MMSE was significantly related to capacity, it did not
fully differentiate participants’ capacity to consent. Of the
participants with moderate AD (MMSE 12–19), 52% were
determined to still have capacity, whereas 15% of those
with mild AD (MMSE 20–26) were determined to lack
capacity. This is similar to other studies that have shown
that individuals with cognitive impairmentmay still have suf-
ficient capacity to give informed consent [33–35]. In a study
of 176 individuals with mild-to-moderate dementia in the
United Kingdom, 24% were unable to give informed consent
according to the country’s legal criteria and the MMSE was
not a significant predictor of capacity in multivariate analyses
[35]. It is unknown whether the use of the ICQ in this study
was causally related to the somewhat unusual findings of
52% of moderate cases being assessed as having capacity
or if cognitive measures are insufficient by themselves to
determine AD patients’ capacity and that more individual-
ized considerations of capacity are warranted [16,35].
The time caregivers spend aiding AD patients with
their day-to-day activities was also significantly related to
capacity in multivariate-adjusted analyses. The ADCS/ADL
functional assessment, however, was only significantly asso-
ciated with capacity in the unadjusted analysis, indicating
the measure did not independently add to the prediction
in the adjusted analyses. Caregiver time, a proxy measure of
the independence of the patient, may better capture the rela-
tionship between a patient’s functioning level and his/her
capacity to consent. The severity of psychological and behav-
ioral problems was not significantly related to capacity in any
of the analyses.
The ICQ was developed to test understanding of the
CSP#546 study, specifically, and research participants’
rights in general. The “passing grade” of 70% correct for
questions 1 to 10 and 100% correct for 11 to 14 was based
on the planning committee’s and IRBs’ assessments of
what constituted a reasonable level of comprehension of
the study and the necessity to fully understand information
related to a participant’s rights and the risks of participation.
The sensitivity analyses on the cut point for an ICQ passing
grade showed that lowering the requirement slightly
increased the level of agreement between the ICQ and the
investigators. We did not require a passing ICQ score
because there is often a need to include a subjective assess-
ment of capacity to take into account the unique circum-
stances and social support of individuals as well as their
cognitive, communication, and insight abilities [35].
We allowed two attempts to “pass” the ICQ to provide an
opportunity to correct any misunderstandings and to more
fully protect participants’ autonomy.We believed that a third
assessment or a repeated teach-to-goal strategy would have
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In a study in nondemented patients who repeated the consent
process and comprehension test until full understanding was
achieved, only 28% of patients answered all comprehension
questions correctly on the first administration [36]. This
increased to 80% on the second administration, suggesting
that a second administration is beneficial and that the major-
ity of individuals achieve understanding by the second test.
In addition to measuring actual understanding of the con-
sent document, the ICQ included an assessment of partici-
pants’ perceived understanding. Perceived understanding
was significantly related to capacity in adjusted and unad-
justed analyses. There was also a significant correlation
between perceived and actual understanding on the ICQ,
indicating that participants’ perception of their understand-
ing was related to their ability to correctly answer questions
about the study; however, the correlation was not strong with
only 33% to 36% of the overall variance in the number of
correct answers explained by perceived understanding.
This correlation was particularly weak in the group with
capacity where only 6% to 8% of the variancewas explained.
A similar finding was seen in a non–cognitively impaired
population where no significant relationship was found be-
tween knowledge and perceptions of being well-informed
[37]. One factor that may contribute to this discordance in
understanding is a possible disagreement between re-
searchers and patients on what is the most important infor-
mation to convey and understand [38,39]. Another possible
factor is that AD patients often have diminished insight
into their cognitive deficits; however, it is not known how
impaired insight relates to performance on cognitive
measures or measures of capacity [16,40]. Nevertheless,
diminished insight is likely to impact a measure of
perceived understanding and may make the measure less
valuable in AD patients. Ideally, measures of actual and
perceived understanding would not differ, but when they
do, it is not clear which construct is more important or
whether a participant should be entered into a study when
they do differ. More research is needed on what should be
done in these situations and whether assessing both
perceived and actual understanding should be considered
to fully respect a participant’s autonomy while also
protecting vulnerable individuals.
While there are some published instruments for assessing
the informed consent process or understanding of consent
documents, none are widely used in research [15,41–45].
The MacArthur Competency Assessment Tool for Clinical
Research (MacCAT-CR), however, has the most empirical
data supporting its use in the clinical setting [15,46,47].
Results from a recent clinical trial of mild-to-moderate AD
suggest that the use of the MacCAT-CR understanding
subscale can help guide judgments about patient’s capacity
to consent in AD research [48]. In another study in mild-
to-moderate AD, however, the authors concluded that stan-
dardized assessment tools may not be that helpful [49].
One reason for the lack of a widely accepted instrument isthat research questions, study procedures, and other details
of disclosure can vary widely among studies, and most pub-
lished measures were either tailored to a specific trial or were
for more general use. We felt that developing an instrument
that measured patient’s specific understanding of the
CSP#546 study would better assist investigators in their
determination of capacity and could be used to identify
specific areas that were not understood so that education in
those areas could be reinforced. Ideally, to better understand
the ICQ’s utility, a general measure such as the MacCAT-CR
could also have been used in the study, and the investigator’s
assessment of capacity could have been done independently
of the ICQ. However, due to practicality and the need for
efficiency, a decision was made to use one simple question-
naire only to aid investigators in capacity assessment.
A limitation of this study was a nearly all-male popula-
tion that may reduce generalizability to women. In addition,
the ICQ and its cutoff score were based solely on face valid-
ity. Finally, although there were guidelines and training for
administering the ICQ, a script was not provided for its
administration or for introduction of the informed consent
itself, which may have led to increased variability in the
ICQ scores and in the determination of capacity to consent.
4.1. Conclusions
In this study of informed consent capacity in an AD clin-
ical trial, we found that the strength of agreement between
the ICQ score and the clinical investigator’s determination
of capacity was “good.” We also found that there were
significant associations between clinical assessment of
capacity and cognitive impairment, caregiver time, race,
and perceived understanding; however, these did not fully
differentiate participants’ capacity to consent. The results
indicate that the use of a study-specific informed consent
questionnaire and assessment of perceived understanding
can be a valuable tool to aid investigators in determining
capacity to consent in AD.
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1. Systematic review: The authors searched the litera-
ture using PubMed for specific studies for deter-
mining capacity to give informed consent in
clinical trials with dementia patients and for objec-
tive tools for assessment of capacity.
2. Interpretation: We assessed the associations between
(1) investigator-determined capacity to consent, (2)
study participants’ characteristics, and (3) a study-
specific measurement of participants’ understand-
ing of the informed consent document in an
Alzheimer’s disease clinical trial. We found signifi-
cant associations between capacity and disease
severity, caregiver time, race, and perceived under-
standing. These results suggest that an objective
measure of understanding at study entry can be a
valuable tool to help determine capacity to consent.
3. Future directions: More research is needed in Alz-
heimer’s disease and in other vulnerable patient pop-
ulations to (1) establish the reliability and validity of
objective tools such as the ICQ and (2) explore the
relationship between perceived and actual under-
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